title: Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model.
abstract: BACKGROUND
  Oral prophylactic therapy by gargling with pathogen-specific egg yolk immunoglobulins (IgY) may reduce the initial airway colonization with Pseudomonas aeruginosa in cystic fibrosis (CF) patients. IgY antibodies impart passive immunization and we investigated the effects of anti-P. aeruginosa IgY antibodies on bacterial eradication in a murine pneumonia model.
  
  
  METHODS
  P. aeruginosa pneumonia was established in Balb/c mice and the effects of prophylactic IgY administration on lung bacteriology, clinical parameters and subsequent inflammation were compared to controls.
  
  
  RESULTS
  Prophylactic administration of IgY antibodies targeting P. aeruginosa significantly reduced the bacterial burden by 2-log 24h post-infection compared to controls and was accompanied by significantly reduced clinical symptom scores and successive inflammatory cytokine profile indicative of diminished lung inflammation.
  
  
  CONCLUSIONS
  Passive immunization by anti-P. aeruginosa IgY therapy facilitates promptly bacterial clearance and moderates inflammation in P. aeruginosa lung infection and may serve as an adjunct to antibiotics in reducing early colonization.
authors: Department of Clinical Microbiology, Rigshospitalet, Copenhagen University Hospital, Denmark. Electronic address: kimsethomsen@gmail.com.
authors: K
authors: K
authors: Thomsen
authors: Department of Clinical Microbiology, Rigshospitalet, Copenhagen University Hospital, Denmark.
authors: L
authors: L
authors: Christophersen
authors: Department of Clinical Microbiology, Rigshospitalet, Copenhagen University Hospital, Denmark; Department of Immunology and Microbiology, Faculty of Health Sciences University of Copenhagen, 2200 Copenhagen, Denmark.
authors: T
authors: T
authors: Bjarnsholt
authors: Department of Clinical Microbiology, Rigshospitalet, Copenhagen University Hospital, Denmark.
authors: P Ø
authors: PØ
authors: Jensen
authors: Department of Clinical Microbiology, Rigshospitalet, Copenhagen University Hospital, Denmark.
authors: C
authors: C
authors: Moser
authors: Department of Clinical Microbiology, Rigshospitalet, Copenhagen University Hospital, Denmark; Department of Immunology and Microbiology, Faculty of Health Sciences University of Copenhagen, 2200 Copenhagen, Denmark.
authors: N
authors: N
authors: Høiby
mesh_terms: D000208:Acute Disease; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000276:immunology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D007136:Immunoglobulins / Q000276:immunology / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D050296:Microbial Viability; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000276:immunology* / Q000302:isolation & purification
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000907:Antibodies, Bacterial; C016512:IgY; D007136:Immunoglobulins
keywords: Cystic fibrosis; IgY; Immunotherapy; Pseudomonas aeruginosa